KRAS (G12V), Isoform B, His-Tag, GppNHp-Loaded Recombinant

Catalog #
101359
$995 *
Size: 4 x 60 µg
Qty
*US Pricing only. For international pricing, please contact your local distributor.
Purchase
Description

Recombinant human KRAS (GTPase), isoform b, encompassing amino acids 2-185. This construct contains an N-terminal His-tag (6xHis). The protein also contains the mutation of interest G12V. The protein (BPS Bioscience #100480) was affinity purified and loaded with GppNHp, a non-hydrolyzable GTP analog. Unbound GppNHp was removed by spin column.

Synonyms
GTPase KRas, K-Ras 2, Ki-Ras, c-K-ras, c-Ki-ras, GTPase KRas, N-terminally processed, KRAS, KRAS2, RASK2
Product Info
Storage and Usage
Citations
Species
Human
Construct
KRAS (G12V) (His-2-185) – (GppNHp)
Mutation
G12V
Host Species/Expression System
Sf9
Purity

≥90%

Format

Aqueous buffer solution

Formulation

20 mM HEPES, pH 7.4, 150 mM NaCl, and 1 mM DTT

MW
22 kDa
Amino Acids
2-185
Genbank #
NM_004985
UniProt #
P01116
Tag(s)
N-terminal His-tag
Background

KRAS (Kirsten rat sarcoma virus) is a GTPase part of the RAS/MAPK pathway, being involved in signal transduction for cell proliferation and differentiation. KRAs is a proto-oncogene and mutations in it are responsible for more than 30% of human cancers, such as leukemia, lung adenocarcinoma, pancreatic and colorectal cancer. Although new treatments have been recently developed to mitigate the tumor-promoting effects of RAS mutations, one mutant, KRAS (G12V), has been resistant to most known inhibitors. New compounds that affect the nucleotide exchange (GDP to GTP) reaction in KRAS mutant G12V are expected to inhibit tumor cell growth in KRAS (G12V)-driven tumors.